A prospective observational cohort study to monitor for hepatotoxicity and regimen discontinuation due to liver related adverse events among People with HIV, initiating Cabotegravir + Rilpivirine regimens (215162) First published 16/02/2022 Last updated 08/10/2025 EU PAS number:EUPAS45568 Study Ongoing